(Total Views: 252)
Posted On: 09/06/2022 7:08:06 PM
Post# of 1460
The below post is copied from IHUB from falconer66a,
Fletch
falconer66a
Re: Steady_T post# 372835
Tuesday, 09/06/2022 6:02:03 PM
Blarcamesine as a contra-aging agent.
Quote:2-73 has functionality further upstream in the disease process than any other drugs I am aware of. It is not a fountain of youth.
Yes, indeed. Blarcamesine (Anavex 2-73) begins its chemical interactions at the sigma-1 receptor protein, which either in normal (non-pathological) processes, or when in blarcamesine-corrected dysfunction, causes all sorts of good, “downstream” things to happen. Properly functioning sigma-1 receptor proteins modulate, facilitate a diversity of consequent, “downstream” processes, including autophagy (waste-clearing and function restoring processes), effective unwrapping of chromatin around DNA (allowing genetic expression of good genes), proper protein (enzyme) folding, and general cell-keeping processes (homeostasis). All of this without side effects of any consequence, even.
But this should be taken into account. Except in very rare cases, where rare untoward genetic anomalies are in control, in most cases of Parkinson’s and Alzheimer’s diseases people suffering from those diseases, earlier in life, had normalized mental functioning. Then, with age, by whatever mechanisms, Parkinson’s and Alzheimer’s set in, with their attendant mental debilities.
What happens when blarcamesine therapy takes effect? To some degree, perhaps rather completely, patients are restored to a more youthful, normalized mental capacity. Blarcamesine has restored earlier and healthful brain and CNS mechanisms. The drug terminated the pathological disease mechanisms and restored the ones in operation in earlier years.
The key consideration is this. Most drugs target and treat symptoms. Stop the symptoms and the disease is treated (it is presumed). Blarcamesine is not targeted at symptoms. As a sigma-1 receptor ligand (chemical attachment) it is specifically targeted at the attachment points on the sigma-1 protein. With that, by its unique modulation of sigma-1 functions, a wide diversity of good things happen “downstream.”
Simply, the Anavex molecule puts things back together the way they were when healthfully functioning in more youthful periods of life. The drug is not just “anti-aging,” slowing or preventing aging processes. It’s actually “contra-aging,” actually reversing to some degree the aging process. Unique, altogether
https://investorshub.advfn.com/boards/read_ms...=169882634
Fletch
falconer66a
Re: Steady_T post# 372835
Tuesday, 09/06/2022 6:02:03 PM
Blarcamesine as a contra-aging agent.
Quote:2-73 has functionality further upstream in the disease process than any other drugs I am aware of. It is not a fountain of youth.
Yes, indeed. Blarcamesine (Anavex 2-73) begins its chemical interactions at the sigma-1 receptor protein, which either in normal (non-pathological) processes, or when in blarcamesine-corrected dysfunction, causes all sorts of good, “downstream” things to happen. Properly functioning sigma-1 receptor proteins modulate, facilitate a diversity of consequent, “downstream” processes, including autophagy (waste-clearing and function restoring processes), effective unwrapping of chromatin around DNA (allowing genetic expression of good genes), proper protein (enzyme) folding, and general cell-keeping processes (homeostasis). All of this without side effects of any consequence, even.
But this should be taken into account. Except in very rare cases, where rare untoward genetic anomalies are in control, in most cases of Parkinson’s and Alzheimer’s diseases people suffering from those diseases, earlier in life, had normalized mental functioning. Then, with age, by whatever mechanisms, Parkinson’s and Alzheimer’s set in, with their attendant mental debilities.
What happens when blarcamesine therapy takes effect? To some degree, perhaps rather completely, patients are restored to a more youthful, normalized mental capacity. Blarcamesine has restored earlier and healthful brain and CNS mechanisms. The drug terminated the pathological disease mechanisms and restored the ones in operation in earlier years.
The key consideration is this. Most drugs target and treat symptoms. Stop the symptoms and the disease is treated (it is presumed). Blarcamesine is not targeted at symptoms. As a sigma-1 receptor ligand (chemical attachment) it is specifically targeted at the attachment points on the sigma-1 protein. With that, by its unique modulation of sigma-1 functions, a wide diversity of good things happen “downstream.”
Simply, the Anavex molecule puts things back together the way they were when healthfully functioning in more youthful periods of life. The drug is not just “anti-aging,” slowing or preventing aging processes. It’s actually “contra-aging,” actually reversing to some degree the aging process. Unique, altogether
https://investorshub.advfn.com/boards/read_ms...=169882634
(1)
(0)Scroll down for more posts ▼
